BioArctic signed a collaboration and licensing agreement with pharmaceutical giant Novartis in August last year. The aim was to explore the possibility of combining an undisclosed proprietary antibody developed by Novartis with BioArctic's BrainTransporter technology, which is designed to help deliver medicines into the brain.
Novartis ends BioArctic deal: “Nothing to do with BrainTransporter”
BioArctic is losing out on potential milestone payments after Novartis decided to discontinue a research programme involving the Swedish company's BrainTransporter technology. Despite the setback, BioArctic says it is pleased with the preclinical data.
Advertisement
BREAKING